Quick search:
Content Ideas
Result | Content Idea | Research |
---|---|---|
Result | Content Idea | Research |
1 | Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer | NEJM |
|
2 | Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination | NEJM |
|
3 | Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 | NEJM |
|
4 | SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia | NEJM |
|
5 | Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center | NEJM |
|
6 | Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination | NEJM |
|
7 | Covid-19 and the Investigator Pipeline |
|
8 | Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas | NEJM |
|
9 | Sunken Nose |
|
10 | New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder |
|
11 | BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers | NEJM |
|
12 | Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization |
|
13 | Preparing for the Future — Nanobodies for Covid-19? | NEJM |
|
14 | Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2 | NEJM |
|
15 | SARS-CoV-2 Antibody Response in Persons with Past Natural Infection | NEJM |
|
16 | Obesity, Immunity, and Cancer |
|
17 | Health Care Worker Strikes and the Covid Pandemic | NEJM |
|
18 | Leveraging Open Science to Accelerate Research |
|
19 | Beyond the Rubble of Lake Street — Minds in Crisis in a City in Crisis |
|
20 | Vancomycin Infusion Reaction — Moving beyond “Red Man Syndrome” | NEJM |
|
21 | Stalking the Diagnosis | NEJM |
|
22 | SARS-CoV-2 Infection after Vaccination in Health Care Workers in California | NEJM |
|
23 | Addressing Workforce Diversity — A Quality-Improvement Framework | NEJM |
|
24 | New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications | NEJM |
|
25 | Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351) | NEJM |
|
26 | “Vaccine Passport” Certification — Policy and Ethical Considerations | NEJM |
|
27 | On the Shoulders of Giants — From Jenner's Cowpox to mRNA Covid Vaccines |
|
28 | New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension |
|
29 | Antibody Mediated Prevention (AMP) trials data published by the New England Journal of Medicine |
|
30 | Addressing Vaccine Hesitancy in BIPOC Communities — Toward Trustworthiness, Partnership, and Reciprocity |
|
31 | New England Journal of Medicine Includes Dallas Hospital Employees in Data in Recent Article |
|
32 | Combating Anti-Asian Sentiment — A Practical Guide for Clinicians |
|
33 | Breathless nejm.org |
|
34 | Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 | NEJM |
|
35 | Medicare's New Device-Coverage Pathway — Breakthrough or Breakdown? | NEJM |
|
36 | Donanemab in Early Alzheimer's Disease |
|
37 | Dying in a Leadership Vacuum nejm.org |
|
38 | Hydroxychloroquine in Hospitalized Patients with Covid-19 – nejm.org |
|
39 | Without Sanctuary nejm.org |
|
40 | SARS-CoV-2 Transmission among Marine Recruits during Quarantine | NEJM |
|
41 | Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 | NEJM |
|
42 | Failed Assignments — Rethinking Sex Designations on Birth Certificates | NEJM |
|
43 | Neutralizing Activity of BNT162b2-Elicited Serum |
|
44 | Covid-19 Vaccine Resources |
|
45 | A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 | NEJM |
|
46 | Microvascular Injury in the Brains of Patients with Covid-19 |
|
47 | Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM |
|
48 | A New Vaccine to Battle Covid-19 | NEJM |
|
49 | Case 30-2020: A 54-Year-Old Man with Sudden Cardiac Arrest |
|
50 | One of Us |
|
51 | Ascaris in the Stomach | NEJM |
|
52 | New NEJM article can serve as diabetes medication resource |
|
53 | BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting | NEJM |
|
54 | Once-Daily Semaglutide Promising for Treating Severe Nonalcoholic Fatty Liver Disease |
|
55 | Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine | NEJM |
|
56 | Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine |
|
57 | Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers | NEJM |
|
58 | Universal Masking in the Covid-19 Era | NEJM |
|
59 | Corneal Bee Sting |
|
60 | The Inequity of Isolation |
|
61 | Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia |
|
62 | Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM |
|
63 | Blood Clots After COVID-19 Vaccination Linked to Immune Response: UK Report |
|
64 | Private Equity and Physician Medical Practices — Navigating a Changing Ecosystem |
|
65 | A Pulsating Leg | NEJM |
|
66 | Bartonella Neuroretinitis |
|
67 | A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia | NEJM |
|
68 | Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621. |
|
69 | A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 | NEJM |
|
70 | The Gift | NEJM |
|
71 | Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults |
|
72 | Beyond Politics — Promoting Covid-19 Vaccination in the United States | NEJM |
|
73 | COVID-19 Scan for Apr 16, 2021 |
|
74 | Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality | NEJM |
|
75 | In a First, New England Journal of Medicine Joins Never-Trumpers |
|
76 | Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma | NEJM |
|
77 | The Stress of Bayesian Medicine — Uncomfortable Uncertainty in the Face of Covid-19 | NEJM |
|
78 | Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia | NEJM |
|
79 | The FDA and the Importance of Trust |
|
80 | KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors |
|
81 | The New Stability | NEJM |
|
82 | Analysis of diversity at premier medical journals met with silence |
|
83 | Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant |
|
84 | Remdesivir for the Treatment of Covid-19 — Final Report | NEJM |
|
85 | Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19 | NEJM |
|
86 | Misrepresenting Race — The Role of Medical Schools in Propagating Physician Bias | NEJM |
|
87 | Telemedicine and Medical Licensure — Potential Paths for Reform |
|
88 | Telephone | NEJM |
|
89 | Hydroxychloroquine with or without Azithromycin in Covid-19 | NEJM |
|
90 | Health Policy in a Biden Administration |
|
91 | Editorial The Covid-19 Vaccine-Development Multiverse |
|
92 | A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 | NEJM |
|
93 | Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine | NEJM |
|
94 | Covid-19 — A Reminder to Reason |
|
95 | Plans and Pandemics |
|
96 | In Pursuit of PPE |
|
97 | Injuries from Less-Lethal Weapons during the George Floyd Protests in Minneapolis | NEJM |
|
98 | Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results | NEJM |
|
99 | Study Finds Magic Mushrooms May Help Fight Depression |
|
100 | Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM |
|